AFC-HD AMS Life Science Co., Ltd. Provides Consolidated Earnings Guidance for the Period Ending February 2023 and August 2023
October 14, 2022 at 07:00 am
Share
AFC-HD AMS Life Science Co., Ltd. provided consolidated earnings guidance for the period ending February 2023 and August 2023. For the period ending February 2023, the company expects consolidated net sales of JPY 12,187 million, operating profit of JPY 682 million, profit attributable to owners of parent of JPY 365 million or JPY 26.00 per basic share.
For the period ending August 2023, the company expects consolidated net sales of JPY 24,741 million, operating profit of JPY 1,481 million, profit attributable to owners of parent of JPY 800 million or JPY 56.99 per basic share.
AFC-HD AMS Life Science Co Ltd is a Japan-based company mainly engaged in the development of the healthcare business and the pharmaceutical business. The Company is engaged in the research and development, product design, manufacture and sale of health foods and cosmetics, manufacture and sale of Chinese medicine medicines, general medicines, generic medicines, healthcare products, the sale of natural foods, as well as planning of health information programs. The Company operates in two business segments. The Healthcare segment is engaged in the manufacture and sale of health foods and cosmetics, as well as the provision of original equipment manufacturers (OEM). The Pharmaceutical segment is engaged in the manufacture and sale of ethical drugs and over-the-counter drugs, as well as the sale of generic drugs. The Company is also engaged in the management of restaurants through subsidiary.
AFC-HD AMS LIFE SCIENCE CO., LTD. 